Post-remission maintenance therapy with AZA has been shown to prolong MRD negativity, and may delay or prevent a relapse and improve OS in elderly patients with AML, including NPM1-mutated AML, independent of the initial MRD status [93]. The gene discussed is NPM1; the disease is acute myeloid leukemia.